- Home
- FLX vs PHAR Comparison
FLX vs PHAR Comparison
Compare FLX & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLX
- PHAR
- Stock Information
- Founded
- FLX 2013
- PHAR 1988
- Country
- FLX China
- PHAR Netherlands
- Employees
- FLX N/A
- PHAR N/A
- Industry
- FLX
- PHAR Biotechnology: Pharmaceutical Preparations
- Sector
- FLX
- PHAR Health Care
- Exchange
- FLX NYSE
- PHAR Nasdaq
- Market Cap
- FLX 603.7M
- PHAR 618.3M
- IPO Year
- FLX 2024
- PHAR N/A
- Fundamental
- Price
- FLX $8.18
- PHAR $8.20
- Analyst Decision
- FLX
- PHAR Strong Buy
- Analyst Count
- FLX 0
- PHAR 3
- Target Price
- FLX N/A
- PHAR $27.00
- AVG Volume (30 Days)
- FLX 18.3K
- PHAR 5.6K
- Earning Date
- FLX 02-27-2025
- PHAR 03-13-2025
- Dividend Yield
- FLX N/A
- PHAR N/A
- EPS Growth
- FLX N/A
- PHAR N/A
- EPS
- FLX 0.19
- PHAR N/A
- Revenue
- FLX $663,142,775.00
- PHAR $285,745,000.00
- Revenue This Year
- FLX N/A
- PHAR $20.08
- Revenue Next Year
- FLX N/A
- PHAR $9.22
- P/E Ratio
- FLX $45.81
- PHAR N/A
- Revenue Growth
- FLX 1.31
- PHAR 30.64
- 52 Week Low
- FLX $6.50
- PHAR $6.65
- 52 Week High
- FLX $21.95
- PHAR $13.20
- Technical
- Relative Strength Index (RSI)
- FLX N/A
- PHAR 36.29
- Support Level
- FLX N/A
- PHAR $8.49
- Resistance Level
- FLX N/A
- PHAR $9.35
- Average True Range (ATR)
- FLX 0.00
- PHAR 0.55
- MACD
- FLX 0.00
- PHAR -0.17
- Stochastic Oscillator
- FLX 0.00
- PHAR 12.14
About FLX BINGEX LIMITED SPON ADS EACH REPR 3 CL A ORD SHS
BingEx Ltd provides on-demand dedicated courier services for individual and business customers with superior time certainty, delivery safety and service quality. The company brands its services as FlashEx, which means delivery in a flash. The Group's principal operations and geographic markets are in the People's Republic of China (PRC).
About PHAR Pharming Group N.V.
Pharming Group is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. It is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines to serve the unserved rare disease patients. Its product includes Ruconest. The revenue is generated from the United States.